Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies

Bourreau, Clara; Treps, Lucas; Faure, Sébastien; Fradin, Delphine; Clere, Nicolas

doi:10.1016/j.pharmthera.2023.108347

Cited by 8 publications

(5 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSCLC is the most frequently diagnosed subtype, accounting for over 80% of all LC cases. The last few decades have witnessed numerous advances made in NSCLC comprehension, leading to early disease detection and therapy development (e.g., thoracoscopic surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy) [22]. Despite this valuable progress, the NSCLC prognosis remains poor, as the majority of the patients already present an advanced disease stage or metastases upon presentation and the current therapy options usually result in acquired resistance [21,22].…”

Section: Discussionmentioning

confidence: 99%

“…The last few decades have witnessed numerous advances made in NSCLC comprehension, leading to early disease detection and therapy development (e.g., thoracoscopic surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy) [22]. Despite this valuable progress, the NSCLC prognosis remains poor, as the majority of the patients already present an advanced disease stage or metastases upon presentation and the current therapy options usually result in acquired resistance [21,22]. RUT is a unique flavonoid chemical possessing numerous pharmacological effects, such as antioxidant, anti-inflammatory, anti-metastatic, and anti-tumor activities [23]; its potential use as an active compound in cancer therapy is being extensively investigated at present.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rutin Linoleate Triggers Oxidative Stress-Mediated Cytoplasmic Vacuolation in Non-Small Cell Lung Cancer Cells

Marcovici,

Vlad,

Buzatu

et al. 2024

Life

View full text Add to dashboard Cite

Lung cancer (LC) represents one of the most prevalent health issues globally and is a leading cause of tumor-related mortality. Despite being one the most attractive compounds of plant origin due to its numerous biological properties, the therapeutic applications of rutin (RUT) are limited by its disadvantageous pharmacokinetics. Thus, the present study aimed to evaluate in vitro the application of two RUT fatty acids bioconjugates, rutin oleate (RUT-O) and rutin linoleate (RUT-L), as potential improved RUT-based chemotherapeutics in non-small cell lung cancer (NSCLC) treatment. The results indicate that both compounds lacked cytotoxic potential in EpiAirway™ tissues at concentrations up to 125 µM. However, only RUT-L exerted anti-tumorigenic activity in NCI-H23 NSCLC cells after 24 h of treatment by reducing cell viability (up to 47%), proliferation, and neutral red uptake, causing cell membrane damage and lactate dehydrogenase (LDH) leakage, affecting cytoskeletal distribution, inducing cytoplasmic vacuolation, and increasing oxidative stress. The cytopathic effects triggered by RUT-L at 100 and 125 µM are indicators of a non-apoptotic cell death pathway that resembles the characteristics of paraptosis. The novel findings of this study stand as a basis for further investigations on the anti-cancer properties of RUT-L and their underlying mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Rutin Linoleate Triggers Oxidative Stress-Mediated Cytoplasmic Vacuolation in Non-Small Cell Lung Cancer Cells

Marcovici,

Vlad,

Buzatu

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…Chen et al ( 72 ) reported that KEAP1 mutation was a potential therapeutic biomarker in patients undergoing immunotherapy. In other types of lung cancer, immunotherapy efficacy-related markers include PD-L1, TMB, MSI/dMMR, POLE/POLD1 mutations, etc ( 73 ). Nevertheless, single and generic predictive markers may not be able to predict the therapeutic efficacy accurately, the specificity of biomarkers could vary depending on tumor type and different ICIs, so relevant predictive markers of efficacy in LCNEC remain to be explored.…”

Section: Treatmentmentioning

confidence: 99%

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Zhu,

Wang,

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma (HGNEC) accounting for 3% of primary lung cancer, and characterized by strong invasion, high heterogeneity, and extremely poor prognosis. At present, the diagnosis and treatment of LCNEC remains controversial and refer to therapeutic strategy of small cell lung cancer (SCLC), lacking precise therapy. Recently, the genetic analysis and clinical trials of LCNEC gradually emerged, providing more evidence for precise diagnosis and treatment. Here, we review the diagnosis, molecular characteristics, and treatment of LCNEC based on the existing research and frontier progress to provide a potential direction for future diagnosis and treatment of LCNEC.

show abstract

“…2 Non-small-cell lung cancer (NSCLC), which is the predominant pathological subtype of lung cancer, constitutes 85 to 90% of all cases. 3 Nearly half of patients are initially diagnosed with earlystage, localized or regional NSCLC, which can be further classified as resectable, potentially resectable or initially unresectable disease according to the status of the tumor and lymph nodes. 4,5 For these three disease classifications, treatment options vary.…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Xia,

Zhang,

Ruan

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

This multicentre, two-arm, phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially unresectable stage II–III non-small-cell lung cancer (NSCLC). Eligible patients regardless of PD-L1 expression received neoadjuvant camrelizumab 200 mg and platinum-doublet chemotherapy every 3 weeks (arm A) or those with PD-L1-positive tumors received neoadjuvant camrelizumab and apatinib 250 mg once daily (arm B), for 2–4 cycles, followed by surgery. The primary endpoint was major pathological response (MPR) rate. Thirty patients in arm A and 21 in arm B were enrolled. Surgery rates were 50.0% (15/30) in arm A and 42.9% (9/21) in arm B, with all patients achieving R0 resections. Of these patients, the MPR and pathological complete response rates were both 20.0% (95% CI 4.3–48.1) in arm A and were 55.6% (95% CI 21.2–86.3) and 11.1% (95% CI 0.3–48.2) in arm B, respectively. The corresponding objective response rates were 33.3% (95% CI 11.8–61.6) and 55.6% (95% CI 21.2–86.3). With a median follow-up of 22.4 months (95% CI 19.0–26.0), the median event-free survival was not reached (NR; 95% CI 13.6-NR) in arm A and 16.8 months (95% CI 8.6-NR) in arm B. Grade 3 or above treatment-related adverse events occurred in eight (26.7%) patients in arm A and three (14.3%) in arm B. Biomarker analysis showed baseline TYROBP expression was predictive of treatment response in arm B. Neoadjuvant camrelizumab plus chemotherapy or apatinib exhibits preliminary efficacy and manageable toxicity in patients with initially unresectable stage II–III NSCLC.

show abstract

Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies

Cited by 8 publications

References 195 publications

Rutin Linoleate Triggers Oxidative Stress-Mediated Cytoplasmic Vacuolation in Non-Small Cell Lung Cancer Cells

Rutin Linoleate Triggers Oxidative Stress-Mediated Cytoplasmic Vacuolation in Non-Small Cell Lung Cancer Cells

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Contact Info

Product

Resources

About